<p>Radiotherapy for patients with completely resected pathologic IIIA(N2) non–small-cell lung cancer: a retrospective analysis</p>

Abstract

Introduction: Adjuvant radiotherapy in non-small-cell lung cancer (NSCLC) remains controversial,Whether the mutation status of epidermal growth factor receptor (EGFR) will affect the recurrence and survival of patients with resected NSCLC is rarely reported. Our purpose is to study the effect of postoperative radiotherapy on patients with stage IIIA(N2) NSCLC with EGFR mutation. Methods: Total of of 115 patients diagnosed with stage IIIA(N2) resected NSCLC were analyzed retrospectively. Their EGFR mutations were detected by real-time quantitative PCR and DNA sequencing technology together. Results: At a median follow-up of 34.2 months for the postoperative adjuvant radiotherapy (PORT) group and 31.0 months for the non-PORT group, PORT group significantly improved progression free survival (PFS) and overall survival (OS). The median PFS and OS in the EGFR mutant group were not significantly longer than those in the EGFR wildtype group. The number of chemotherapy cycles, postoperative radiotherapy and the number of metastatic lymph nodes were independent factors influencing long-term survival. Conclusion: Our retrospective analysis showed that PORT can improve survival of patients with stage IIIA(N2) NSCLC. EGFR-mutant group with stage IIIA(N2) NSCLC has a tendency of a higher survival than the wild-type EGFR group, but there was no significant difference for both groups. The EGFR mutation status was not associated with PFS or OS of stage IIIA(N2) NSCLC.

Effect of postoperative radiotherapy on survival in patients with completely resected and pathologically confirmed stage N2 non-small-cell lung cancer: a systematic review and meta-analysis

“…In all, 20 studies 13,18,[21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] were finally included after literature screening, including 6 randomized controlled trials and 14 retrospective studies. A total of 6340 patients were enrolled, of which 1972 patients received PORT and 4368 patients did not.…”

The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma

“… 14 , 15 , 17 The prognostic significance of EGFR mutation status in patients who underwent PORT was unclear. 18 , 19 In our study, the results revealed that PORT was not associated with better survival outcomes in pⅢA-N2 NSCLC with EGFR mutation, which suggested that targeted therapy may be a more suitable adjuvant treatment option. For EGFR wild-type patients, the options for adjuvant therapies are limited.…”

The Role of Postoperative Radiation Therapy for pN2 Non–small-cell Lung Cancer

“…11 Some studies demonstrated a possible PORT benefit in specific patient subsets, including pN2 squamous cell cancer 34 and pN2 EGFR-mutant NSCLC. 35 Our study has several limitations inherent in retrospective database methodology. Although we attempted to account for nonrandom selection of patients with PS matching and IPTW, PORT for pN2 NSCLC e14 -Clinical Lung Cancer January 2021 confounding by variables not captured in SEER may exist.…”